# Editorial: Pharmacological and nutritional approaches to metabolic associated fatty liver disease: a step towards achieving SDG 3

**Authors:** Mahmut Bodur, Bojana Vidović, Anastasios Nikolaou, Birsen Yilmaz

PMC · DOI: 10.3389/fphar.2026.1802444 · Frontiers in Pharmacology · 2026-02-17

## Full-text entities

- **Genes:** ERN1 (endoplasmic reticulum to nucleus signaling 1) [NCBI Gene 2081] {aka IRE1, IRE1P, IRE1a, hIRE1p}, SLC11A1 (solute carrier family 11 member 1) [NCBI Gene 6556] {aka LSH, NRAMP, NRAMP1}
- **Diseases:** immune-mediated liver injury (MESH:D017093), T2DM (MESH:D003924), inflammation (MESH:D007249), MASLD (MESH:D008107), MAFLD (MESH:D005234), obesity (MESH:D009765), metabolic dysregulation (MESH:D021081), abnormal thyroid function (MESH:D013966), metabolic disorder (MESH:D008659)
- **Chemicals:** FT3 (-), resmetirom (MESH:C588408), lipid (MESH:D008055), fat (MESH:D005223), iron (MESH:D007501)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953502/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953502/full.md

---
Source: https://tomesphere.com/paper/PMC12953502